Related references
Note: Only part of the references are listed.Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluoruracil in patients with squamous cell carcinoma of the esophagus
Stefan Muench et al.
RADIATION ONCOLOGY (2018)
Radiation dose in neoadjuvant chemoradiation therapy for esophageal cancer: patterns of care and outcomes from the National Cancer Data Base
Waqar Haque et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2018)
The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer
S. Vivekanandan et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy
Mian Xi et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2017)
Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy
Kyle Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Heart Dose Is an Independent Dosimetrie Predictor of Overall Survival in Locally Advanced Non-Small Cell Lung Cancer
Christina K. Speirs et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/ 5-fluoruracil in patients with squamous cell carcinoma of the esophagus
Stefan Muench et al.
RADIATION ONCOLOGY (2017)
Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy
N. Nabavizadeh et al.
DISEASES OF THE ESOPHAGUS (2016)
ypN0: Does It Matter How You Get There? Nodal Downstaging in Esophageal Cancer
Andrea Zanoni et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Radiation Esophagitis
Diana Murro et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2015)
Locally Advanced Esophageal Chemoradiation Therapy Practice Patterns: Results From a National Survey of ASTRO Members
D. A. Elliott et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
Jeffrey D. Bradley et al.
LANCET ONCOLOGY (2015)
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
Joel Shapiro et al.
LANCET ONCOLOGY (2015)
Is cardiac toxicity a relevant issue in the radiation treatment of esophageal cancer?
Jannet C. Beukema et al.
RADIOTHERAPY AND ONCOLOGY (2015)
Tumor Stage After Neoadjuvant Chemotherapy Determines Survival After Surgery for Adenocarcinoma of the Esophagus and Esophagogastric Junction
Andrew R. Davies et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Patterns of Recurrence After Surgery Alone Versus Preoperative Chemoradiotherapy and Surgery in the CROSS Trials
Vera Oppedijk et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Surgery Alone Versus Chemoradiotherapy Followed by Surgery for Stage I and II Esophageal Cancer: Final Analysis of Randomized Controlled Phase III Trial FFCD 9901
Christophe Mariette et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Neoadjuvant or Adjuvant Therapy for Resectable Esophageal Cancer: Is There a Standard of Care?
Khaldoun Almhanna et al.
CANCER CONTROL (2013)
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
P. van Hagen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
Marc Ychou et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Complete Pathologic Response After Neoadjuvant Chemoradiotherapy for Esophageal Cancer Is Associated With Enhanced Survival
James M. Donahue et al.
ANNALS OF THORACIC SURGERY (2009)
The extreme radiosensitivity of the squamous cell carcinoma SKX is due to a defect in double-strand break repair
Ulla Kasten-Pisula et al.
RADIOTHERAPY AND ONCOLOGY (2009)
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781
Joel Tepper et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Downstaging of T or N predicts long-term survival after preoperative chemotherapy and radical resection for esophageal carcinoma
Robert J. Korst et al.
ANNALS OF THORACIC SURGERY (2006)
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial
BH Burmeister et al.
LANCET ONCOLOGY (2005)
A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma
JL Lee et al.
ANNALS OF ONCOLOGY (2004)
Risk factors for esophageal cancer and the multiple occurrence of carcinoma in the upper aerodigestive tract
M Morita et al.
SURGERY (2002)
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma
SG Urba et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
